Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine acts as an alpha‑1 adrenergic receptor agonist. By stimulating these receptors on the radial muscles of the iris, it causes contraction of the dilator muscle, leading to pupil enlargement. This effect works together with tropicamide’s antimuscarinic action to achieve full mydriasis.

The specific dosing regimen for Mydriasert is determined by the prescribing ophthalmologist based on the patient’s age, clinical need, and response. Typically, a single drop is instilled in each eye, but the exact amount and frequency should follow the prescriber’s instructions.

Safety data for Mydriasert during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate the individual situation and discuss alternatives when appropriate.

To order Mydriasert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Mydriasert combines an alpha‑agonist (phenylephrine) with an antimuscarinic (tropicamide), offering both rapid onset and prolonged dilation. Single‑agent preparations may provide only one mechanism, potentially requiring higher concentrations or repeated dosing to achieve comparable mydriasis.

Mydriasert should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from light and moisture, and keep the container tightly closed when not in use to maintain sterility and potency.

Mydriasert is applied topically to the eye. The usual method is to instill one drop into the conjunctival sac of each eye, as directed by the ophthalmologist. The patient should avoid touching the dropper tip to any surface to preserve sterility.

The most serious risks include acute angle‑closure glaucoma, which can cause sudden severe eye pain and vision loss, and systemic hypertension due to phenylephrine absorption. An allergic reaction presenting as swelling, itching, or rash around the eye also requires immediate medical attention.

Mydriasert should be avoided in patients with known narrow‑angle or uncontrolled glaucoma, severe cardiovascular disease, uncontrolled hypertension, or a documented hypersensitivity to phenylephrine, tropicamide, or any excipients in the formulation.